{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:41:34Z","timestamp":1794271294506,"version":"4.9.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range [IQR], 56-80). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166). The median number of therapies before fostamatinib initiation was 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%), and IV immunoglobulins (44.2%). Fifty-eight patients (42.0%) had signs\/symptoms of bleeding in the month before treatment initiation. Seventy-nine percent of patients responded to fostamatinib with 53.6% complete responses (platelet count &amp;gt; 100\u00a0\u00d7 109\/L). Eighty-three patients (60.1%) received fostamatinib monotherapy, achieving a high response rate (85.4%). The proportion of time in response during the 27-month period examined was 83.3%. The median time to platelet response was 11 days (IQR, 7-21). Sixty-seven patients (48.5%) experienced adverse events, mainly grade 1 to 2; the commonest of which were diarrhea (n\u00a0=\u00a028) and hypertension (n\u00a0=\u00a021). One patient had deep venous thrombosis, and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024250","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:58:17Z","timestamp":1717689497000},"page":"646-656","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-1816","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-0318","authenticated-orcid":false,"given":"Nuria","family":"Bermejo-Vega","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Complejo Hospitalario Universitario de C\u00e1ceres, C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Cardesa-Cabrera","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital P\u00fablico Comarcal de La Merced, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Mart\u00ednez-Robles","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0767-9172","authenticated-orcid":false,"given":"Gerardo","family":"Aguilar-Monserrate","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Cl\u00ednico Universitario de Valladolid, Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1322-6065","authenticated-orcid":false,"given":"Gloria","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Domingo","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Fundaci\u00f3 Privada Hospital Asil de Granollers, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Luis-Navarro","sequence":"additional","affiliation":[{"name":"8Department of Hematology Hospital General de Riotinto, Minas de Riotinto, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-4839","authenticated-orcid":false,"given":"Sunil","family":"Lakhwani","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Acedo","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-7037","authenticated-orcid":false,"given":"Mar\u00eda Luisa","family":"Lozano","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital General Universitario Jos\u00e9 Mar\u00eda Morales Meseguer, Centro Regional de Hemodonaci\u00f3n, Universidad de Murcia, IMIB-Pascual Parrilla, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras- Instituto de Salud Carlos III, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bernat","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Hospital Universitario de La Plana, Villareal, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-5124","authenticated-orcid":false,"given":"Ana","family":"Torres-Tienza","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Complejo Asistencial de Segovia, Segovia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruano","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9993-6857","authenticated-orcid":false,"given":"Pilar","family":"Gal\u00e1n","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Complejo Asistencial de Segovia, Segovia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Benet","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Hospital Arnau de Vilanova, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shally","family":"Marcellini","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Complejo Asistencial de Segovia, Segovia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-1021","authenticated-orcid":false,"given":"Reyes","family":"Jimenez-B\u00e1rcenas","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Hospital de la Serran\u00eda de Ronda, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mart\u00ednez-Carballeira","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunia","family":"De Miguel-Llorente","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Perona-Bl\u00e1zquez","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-1704","authenticated-orcid":false,"given":"Isabel","family":"Gonzalez-Gasc\u00f3n","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4014-6808","authenticated-orcid":false,"given":"Elsa","family":"Lopez-Ansoar","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Hospital Universitario \u00c1lvaro Cunqueiro, Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Alonso-Alonso","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Complejo Asistencial de Palencia, Palencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Bengochea-Casado","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hospital Universitario Severo Ochoa, Legan\u00e9s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"D\u00edaz-G\u00e1lvez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moret\u00f3","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Hospital Universitario de Cruces, Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Moreno-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Hern\u00e1ndez-Martin","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Complejo Asistencial de Zamora, Zamora, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-5594","authenticated-orcid":false,"given":"Erik","family":"de Cabo","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Complejo Hospital de El Bierzo, Ponferrada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2073","authenticated-orcid":false,"given":"Julio","family":"D\u00e1vila-Valls","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Complejo Asistencial de Avila, Avila, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Cuesta","sequence":"additional","affiliation":[{"name":"30Department of Hematology, Hospital Sierrallana, Cantabria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pastoriza","sequence":"additional","affiliation":[{"name":"31Department of Hematology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Julio","family":"Hermida-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Pozas-Ma\u00f1as","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Hospital Universitario R\u00edo Hortega, Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5225-6687","authenticated-orcid":false,"given":"Carlos","family":"Aguilar","sequence":"additional","affiliation":[{"name":"33Department of Hematology, Complejo Asistencial de Soria, Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Fernandez-Jimenez","sequence":"additional","affiliation":[{"name":"34Department of Hematology, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Navas-Elorza","sequence":"additional","affiliation":[{"name":"35Department of Hematology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2507-2380","authenticated-orcid":false,"given":"Carolina","family":"L\u00f3pez-Santamar\u00eda Castro","sequence":"additional","affiliation":[{"name":"36Department of Hematology, Hospital Universitario de Badajoz, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8761-3220","authenticated-orcid":false,"given":"Alvaro","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"37Department of Hematology, Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ort\u00edn","sequence":"additional","affiliation":[{"name":"38Department of Hematology, Hospital Verge de la Cinta, Tortosa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"39Department of Hematology, Hospital de Terrassa, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Piernas","sequence":"additional","affiliation":[{"name":"40Department of Hematology, Parc Taul\u00ed Hospital Universitari, Sabadell, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana","family":"D\u00edaz-Santa","sequence":"additional","affiliation":[{"name":"41Department of Hematology, Hospital Universitari Doctor Josep Trueta, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-4411","authenticated-orcid":false,"given":"Inmaculada","family":"Soto","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-8455","authenticated-orcid":false,"given":"Drew","family":"Provan","sequence":"additional","affiliation":[{"name":"42Department of Haematology, Barts and The London School of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Garc\u00eda-Donas Gabald\u00f3n","sequence":"additional","affiliation":[{"name":"43Department of Hematology, Hospital Universitario Virgen Macarena, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024080815203481300_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2010.08412.x","article-title":"Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters","volume":"152","author":"Toltl","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2024080815203481300_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00062752-199603050-00001","article-title":"Diagnosis, clinical course, and management of idiopathic thrombocytopenic purpura","volume":"3","author":"George","year":"1996","journal-title":"Curr Opin Hematol"},{"issue":"13","key":"2024080815203481300_bib3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024080815203481300_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2024080815203481300_bib5","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2024080815203481300_bib6","first-page":"535","article-title":"Incidence and aetiology","volume":"191","author":"B\u00f6ttiger","year":"1972","journal-title":"Acta Med Scand"},{"issue":"19","key":"2024080815203481300_bib7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM198105073041904","article-title":"Chronic idiopathic thrombocytopenic purpura","volume":"304","author":"McMillan","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024080815203481300_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2007-1005045","article-title":"Autoimmune platelet destruction: idiopathic thrombocytopenic purpura","volume":"8","author":"Kelton","year":"1982","journal-title":"Semin Thromb Hemost"},{"key":"2024080815203481300_bib9","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"2024080815203481300_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"2024080815203481300_bib11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in\u00a0vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2024080815203481300_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in\u00a0vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2024080815203481300_bib13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2024080815203481300_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","journal-title":"Eur J Haematol"},{"issue":"2","key":"2024080815203481300_bib15","first-page":"16","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"2024080815203481300_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"suppl 7","key":"2024080815203481300_bib17","first-page":"10","article-title":"Purpura trombocitopenica inmune. Fisiopatologia y epidemiologia","volume":"94","author":"Grande","year":"2009","journal-title":"Haematologica"},{"issue":"suppl 71","key":"2024080815203481300_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0609.2008.01206.x","article-title":"Immune thrombocytopenic purpura: epidemiology and implications for patients","volume":"82","author":"Michel","year":"2009","journal-title":"Eur J Haematol"},{"issue":"6","key":"2024080815203481300_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"key":"2024080815203481300_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0028-1086135","article-title":"Management of idiopathic thrombocytopenic purpura in the adult","volume":"3","author":"Lacey","year":"1977","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2024080815203481300_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024080815203481300_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2024080815203481300_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024080815203481300_bib24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"2024080815203481300_bib25","first-page":"653","article-title":"Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice","volume":"12","author":"Song","year":"2021","journal-title":"J\u00a0Blood Med"},{"issue":"20","key":"2024080815203481300_bib26","first-page":"6422","article-title":"Recommendations for the clinical approach to immune thrombocytopenia: Spanish ITP Working Group (GEPTI)","volume":"12","author":"Mingot-Castellano","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"2024080815203481300_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"2024080815203481300_bib28","doi-asserted-by":"crossref","first-page":"20406207211010875","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"2024080815203481300_bib29","first-page":"9953245","article-title":"Two refractory immune thrombocytopenia case reports showing responsiveness to fostamatinib","volume":"2023","author":"Innao","year":"2023","journal-title":"Case Rep Hematol"},{"issue":"2","key":"2024080815203481300_bib30","doi-asserted-by":"crossref","first-page":"e13462","DOI":"10.1016\/j.heliyon.2023.e13462","article-title":"Sustained response off therapy after fostamatinib: a chronic refractory ITP case report","volume":"9","author":"Auteri","year":"2023","journal-title":"Heliyon"},{"key":"2024080815203481300_bib31","doi-asserted-by":"crossref","first-page":"8119270","DOI":"10.1155\/2022\/8119270","article-title":"The efficacy and safety of fostamatinib in elderly patients with immune thrombocytopenia: a single-center, real-world case series","volume":"2022","author":"Liu","year":"2022","journal-title":"Adv Hematol"},{"issue":"2","key":"2024080815203481300_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000520438","article-title":"Real-world use of fostamatinib in patients with immune thrombocytopenia and thrombotic risk","volume":"145","author":"Mehta","year":"2022","journal-title":"Acta Haematol"},{"issue":"5","key":"2024080815203481300_bib33","first-page":"508","article-title":"Transitioning from thrombopoietin agonists to the novel SYK inhibitor fostamatinib: a multicenter, real-world case series","volume":"12","author":"Hughes","year":"2021","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"2024080815203481300_bib34","unstructured":"Tavlesse\n          . Summary of product characteristics. Grifols. Date of revision: september 2022. Accessed 12 February 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tavlesse."},{"issue":"5","key":"2024080815203481300_bib35","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/bjh.19443","article-title":"Treatment with fostamatinib in patients with immune thrombocytopenia: experience from the Andalusian region in Spain-the fostasur study","volume":"204","author":"Jim\u00e9nez-B\u00e1rcenas","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"2024080815203481300_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2024080815203481300_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2024080815203481300_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.16958","article-title":"Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy","volume":"190","author":"Kapur","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2024080815203481300_bib39","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.17800","article-title":"Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study","volume":"196","author":"Meyer","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2024080815203481300_bib40","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"2024080815203481300_bib41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/medicina59040659","article-title":"Sustained remission off-treatment (SROT) of TPO-RAs: the burgos ten-step eltrombopag tapering scheme","volume":"59","author":"Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"23","key":"2024080815203481300_bib42","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024080815203481300_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.27131","article-title":"Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial","volume":"99","author":"Cooper","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"2024080815203481300_bib44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2024080815203481300_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12725","article-title":"Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice","volume":"97","author":"Gonz\u00e1lez-L\u00f3pez","year":"2016","journal-title":"Eur J Haematol"},{"issue":"17","key":"2024080815203481300_bib46","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2011-11-393900","article-title":"In\u00a0vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation","volume":"119","author":"Psaila","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2024080815203481300_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/646\/2237308\/blood_bld-2024-024250-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/646\/2237308\/blood_bld-2024-024250-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T11:21:12Z","timestamp":1723116072000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/6\/646\/516388\/Fostamatinib-effectiveness-and-safety-for-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024250","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}